“The submission of the PMA supplement to the FDA for our second-generation LungFit PH device, which we announced yesterday, could be transformative for our business,” continued Lisi. “If approved, we believe this new system will unlock significant market potential. Coupled with our global expansion and rising brand recognition, we are entering what we believe will be an exciting and pivotal year for Beyond Air (XAIR) and our shareholders.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XAIR:
- Beyond Air reports Q4 EPS (9c) vs. (37c) last year
- Options Volatility and Implied Earnings Moves Today, June 17, 2025
- Beyond Air submits FDA PMA supplement for LungFit PH
- Options Volatility and Implied Earnings Moves This Week, June 16 – June 20, 2025
- XAIR Earnings Report this Week: Is It a Buy, Ahead of Earnings?